Affordable Access

[Successful treatment of angiosarcoma with liposomal-encapsulated doxorubicin].

Authors
  • 1
  • 1 Klinik und Poliklinik für Haut- und Geschlechtskrankheiten, Universität Würzburg.
Type
Published Article
Journal
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
1432-1173
Publication Date
Volume
52
Issue
10
Pages
895–898
Identifiers
PMID: 17690822
Source
Medline
License
Unknown

Abstract

Cutaneous angiosarcoma is a rare tumor of endothelial origin, often difficult to diagnose and with an unfavorable prognosis. A 85-year-old woman presented with an extensive angiosarcoma involving her right leg. The tumor was not clinically typical but the diagnosis was confirmed histologically. Because of her age and the extent of the tumor, we elected to treat primarily with cobalt-60 irradiation. The tumor unfortunately progressed during radiation therapy, so we decided to begin palliative chemotherapy with liposome-encapsulated doxorubicin. The patient received six cycles of doxorubicin (Caelyx, 15 mg/m(2) i.v. in four-week intervals) which was well-tolerated and led to complete regression of angiosarcoma which has lasted for 6 months. Chemotherapy with liposome-encapsulated doxorubicin may represent a well-tolerable therapeutic option in cases where surgery and irradiation are not possible or fail. Further studies are necessary to prove the efficacy of doxorubicin therapy in angiosarcoma.

Statistics

Seen <100 times